ROLE OF URINARY INHIBITORS AND PROMOTERS IN CALCIUM OXALATE CRYSTALLISATION

Monika Gupta1*, Seema Bhayana2 and S.K. Sikka3

1Department of Chemistry, Vaish (P.G.) College, Rohtak, Haryana, India.
2UIET, M.D.University, Rohtak, Haryana, India.
3Vaish (P.G.) College, Rohtak, Haryana, India.

*Corresponding Author: guptamonika77@yahoo.com

ABSTRACT

Urine of most people is supersaturated with stone forming constituents, including calcium, oxalate, phosphate and uric acid. Crystals or foreign bodies can act as nuclei, upon which ions from the supersaturated urine form microscopic crystalline structures. The majority of urinary calculi contain calcium. Calcium stones occur when urine becomes supersaturated with calcium oxalate and phosphate. They form crystals that bind into hardened mineral deposits known as renal stones. The process of stone formation includes crystal nucleation, growth, aggregation and retention. Various substances in our urine modify these stone forming processes, thereby influencing a person's ability to promote or inhibit stone formation. Promoters of stone formation facilitate stone formation while inhibitors prevent it. Low urine volume, low urine pH, calcium, sodium, oxalate, and urate are known to promote stone formation. Many inorganic (e.g., Citrate, magnesium, pyrophosphate etc.) and organic (e.g., Tamm-Horsfall protein, glycosaminoglycans, uropontin, nephrocalcin, renal lithostathine etc.) substances, high urine volume are known to inhibit stone formation. This paper presents role of urinary inhibitors and promoters in calcium oxalate crystallization.

Keywords: Renal stones, urinary calculi, promoters and inhibitors.

1. INTRODUCTION

Urine is a more complex solution, and is often supersaturated with respect to stone forming substances. But crystallization does not occur in urine because urine has the capacity to hold more solute than water as it contains a mixture of many electrically active ions that interact with each other, affecting their solubility. The presence of organic molecules, such as urea, uric acid and citrate, Tamm-Horsfall protein, glycosaminoglycans, uropontin, etc. affects the solubility of other substances.1 Urine can hold large concentrations of solute above the solubility product, Ksp, and is therefore described as being 'metastable'. As the concentration of the substance is increased further, a point is reached when it can no longer be held in solution and get crystallizes and this concentration is known as the ‘formation product’ (Kf) of the substance. The formation product is the level of saturation at which solute no longer remains in solution and spontaneous nucleation occurs. The formation of urinary calculi requires a complex combination of factors; both promoting and inhibiting stone formation.2 Coe et al found that inhibitory activity was low in urine of
stone formers as compared to normal subjects.³

2. INHIBITORS AND PROMOTERS
Inhibitors are the molecules which increase the supersaturation required to initiate nucleation, decrease the crystal growth and aggregation and inhibit secondary nucleation (deposition of new crystals on pre-existing crystal surfaces of similar type) whereas promoters causes reduction of the formation product of the supersaturated solution. The loss of balance between the urinary promoters and inhibitors has been suggested to increase the risk of stone formation more than disturbance in any single substance. The Table 1 give a brief idea about inhibitors and promoters of stone formation.

<table>
<thead>
<tr>
<th>Table 1: Inhibitors and Promoters of kidney stones</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Inhibitors</strong></td>
</tr>
<tr>
<td>Inorganic-</td>
</tr>
<tr>
<td>Citrate</td>
</tr>
<tr>
<td>Magnesium</td>
</tr>
<tr>
<td>Pyrophosphate</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>High urine volume</td>
</tr>
</tbody>
</table>

2.1 Inhibitors
Inhibitors slow or inhibit the rate of growth or aggregation of crystals or reduce adherence of crystals to the renal epithelium. Many inorganic and organic substances, high urine volume are known to inhibit crystal growth, aggregation and adhesion as shown in Table 2.

<table>
<thead>
<tr>
<th>Table 2: Effects of Inhibitors on Crystallization</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Name of Inhibit</strong></td>
</tr>
<tr>
<td>Citrate</td>
</tr>
<tr>
<td>Magnesium</td>
</tr>
<tr>
<td>Pyrophosphate</td>
</tr>
<tr>
<td>Osteopontin</td>
</tr>
<tr>
<td>Urinary Prothrombin fragment1</td>
</tr>
<tr>
<td>Tamm-Horsfall protein (THP)</td>
</tr>
<tr>
<td>Glycosaminoglycans (GAGs)</td>
</tr>
<tr>
<td>Renal Lithostathine (RL)</td>
</tr>
<tr>
<td>Nephrocalcin (NC)</td>
</tr>
</tbody>
</table>

2.1.1 Inorganic inhibitors - Among inorganic inhibitors shown in Table 1, Citrate is the most important inhibitor. Magnesium may act indirectly by increasing urinary citrate levels. Pyrophosphate acts as inhibitor by reducing the absorption of calcium. These three inorganic inhibitors are discussed in the following sub-sections.

2.1.1.1. Citrate
Citric acid is a tricarboxylic acid that circulates in blood complexed to calcium, magnesium and sodium at physiological pH of 7.4. It is derived from both endogenous (Kreb's cycle) and exogenous sources (citrus fruits like orange and grapes). Any condition that results in intracellular acidosis, high protein diet and exercise will cause a decrease in urinary citrate concentrations. Parathormone (PTH),
magnesium, lithium, calcitonin, and vitamin D have been found to increase urinary citrate levels. Citrate is a potent inhibitor of calcium oxalate and phosphate stones in particular. Citrate seems to be an altering factor of both calcium oxalate monohydrate (thermodynamically most stable form) and calcium phosphate crystallization.\(^4\) It forms complex with calcium thereby reducing the concentration of calcium oxalate. Citrate also increases the stone aggregation inhibitory activity of other urine macromolecules (e.g. THP) and may reduce the expression of urinary osteopontin, an important component of the protein matrix of urinary stones.\(^5\)

Moreover; urinary citrate excretion can increase urinary pH, a factor in the calcium-citrate-phosphate complex formation. Urinary alkalinization of potassium citrate increases the solubility of uric acid thus preventing the salting out of calcium oxalate by urate.\(^6\)

### 2.1.1.2. Magnesium

Magnesium is the fourth most abundant mineral in the body and is largely found in bones.

In a supersaturated calcium oxalate solution 2.0 mmol/L magnesium was shown to reduce crystal growth by 50%.\(^7\) Magnesium can form complexes with oxalate thereby decreasing supersaturation. Oral intake of magnesium appears to decrease the oxalate absorption and urinary excretion, in a manner similar to calcium by binding to oxalate in the gut.\(^8\) Subjects with magnesium deficiency after being provided with magnesium supplements showed increase of excretion of citrate in urine.\(^9\)

### 2.1.1.3. Pyrophosphate

Pyrophosphate is a potent inhibitor of crystal growth and in some cases also of crystal aggregation. At low concentrations, 16µM, pyrophosphate inhibits calcium oxalate monohydrate crystal growth by 50%.\(^10\) The urinary pyrophosphate levels (20-40µM) are theoretically high enough to inhibit calcium oxalate and calcium phosphate crystallisation. This was confirmed by Sharma et al who reported low 24-hour urinary excretion of pyrophosphate in stone formers as compared to non stone formers.\(^11\)

### 2.1.2. Organic inhibitors

**Osteopontin**, Urinary prothrombin fragment 1 (UPTF1), Tamm-Horsfall protein, glycosaminoglycans, renal lithostathine, nephrocalcin etc. are some organic inhibitors shown in Table 1, which inhibit the crystallization and are discussed in the following sub-sections.

#### 2.1.2.1. Osteopontin (Uropontin)

This is a negatively-charged aspartic acid rich protein that inhibits growth of calcium oxalate crystals in a supersaturated solution. It is synthesized within the kidney and present in the human urine at levels in excess of 100 nM.\(^12\) It is an abundant component of organic matrix of calcium oxalate stones. In vitro studies suggest osteopontin may inhibit nucleation, growth and aggregation of calcium oxalate crystals and also inhibits the crystal adhesion to renal epithelial cells. Some studies have reported decreased concentrations of OPN in urine of stone formers as compared to normal individuals.\(^13\)

#### 2.1.2.2. Urinary prothrombin fragment 1 (UPTF1)

This is a potent inhibitor of calcium oxalate stone formation in vitro.\(^14\) The organic matrix of calcium oxalate crystals contains UPTF1, providing evidence that links the role of blood coagulation proteins with stone formation. UPTF1 is an important inhibitor of calcium oxalate crystal growth, aggregation and adherence of crystals to renal cells.\(^15\)

#### 2.1.2.3. Tamm-Horsfall Protein (THP)

Tamm-Horsfall protein (isolated by Tamm and Horsfall 50 years ago) is the most abundant glycoprotein in the urine of normal mammals. There is a lot of controversy about whether this protein is an inhibitor or promoter of kidney stone. Most believe it to be an effective inhibitor of calcium oxalate monohydrate crystals aggregation along with high pH, low ionic strength and low concentrations of divalent ions in a solution whereas low pH, high concentrations of calcium, sodium and hydrogen ion and low THP in a solution can act as promoters of aggregation.\(^16\) THP has no inhibitory activity against crystal nucleation rather it promotes nucleation as shown in Table 2. It self aggregates into protein particles in high calcium and sodium, and low pH.\(^17\)

#### 2.1.2.4. Glycosaminoglycans (GAGs)

GAGs are enzymatic products of proteoglycans and have been identified as one
of the macromolecules present in the stone matrix. They are believed to play an important role in calcium oxalate crystallisation. They have the ability to inhibit the growth and aggregation of calcium oxalate crystals by blocking the growth sites. They also prevent crystal adhesion to renal cells, which is an important step in renal stone formation. However, no study shows qualitative or quantitative significant difference in total excretion of glycosaminoglycans between stone formers and non stone formers.

2.1.2.5. Renal Lithostathine
Renal Lithostathine, a protein of pancreatic secretion, is a urinary inhibitor of calcium carbonate crystal growth. Several studies showing the presence of calcium carbonate in renal stones suggested that crystals of calcium carbonate might be present in the early steps of stone formation. Such crystals might therefore promote calcium oxalate crystallization from supersaturated urine by providing an appropriate substrate for heterogeneous nucleation.

2.1.2.6. Nephrocalcin (NC)
NC is composed of 110 amino acid residues of which 25% are glutamic and aspartic acid. It contains two cysteine and two or three γ-carboxyglutamic acid (Gla) residues which are suggested to play a significant part in its ability to inhibit calcium oxalate crystallization. One mole of Nephrocalcin binds 4 moles of Ca\(^{2+}\) and its binding sites differ completely from those in other Ca\(^{2+}\)-binding proteins. Nephrocalcin is produced in human kidney by proximal tubule and the thick ascending limb of Henle's loop. Coe et al. isolated nephrocalcin that inhibits calcium oxalate crystal growth by absorption to crystal surfaces from urine, kidney tissue and calcium oxalate stones. Nephrocalcin inhibits nucleation and aggregation of calcium oxalate stones and crystal adhesion to renal cells.

2.1.3. High urine volume
One of the most important inhibitors of stone formation is high urine volume. A high volume of urine helps to reduce the relative supersaturation of the crystal forming components. Moreover, high volume indicates high urine flow rates, which tends to wash out any crystals formed already. One randomised clinical study going for five years showed stones recurred in only 12 out of 99 patients maintaining a urine volume of about 2.6L/day.

2.2 Promoters
Urine contains substances that influence crystallization processes, and therefore regulate stone formation. Substances that increase crystallization are termed promoters. Low urine volume, low urine pH, calcium, sodium, oxalate, and urate are known to promote stone formation. On the cell surfaces of the kidney, cell debris, protein aggregates and other crystals may provide site for nucleation which might lower the supersaturation required to initiate crystallisation thereby promoting calcium oxalate crystallisation. There are strong geometric similarities between the crystals of uric acid dihydrate and calcium oxalate monohydrate which may promote overgrowth of one on the other. Another factor that promotes the formation and growth of intrarenal crystals is ionic calcium. Hypercalciuria can decrease inhibitory activity and promotes crystallisation. Furthermore, cellular responses to newly formed crystals and factors that modulate these crystal-cell interactions could stimulate the formation of renal stone. The role of cell injury may be an even more important determinant in the promotion and progression of kidney stones.

3. CONCLUSION
Renal stone formation is initiated by supersaturation of urinary salts and crystal retention in the urinary tract. Stone formation is a multi-step process viz. nucleation, crystal growth; aggregation and retention are necessary steps in formation of stones. However, urine contains many substances that modify and inhibit the process of stone formation. Magnesium, pyrophosphate, citrate, nephrocalcin, osteopontin, glycosaminoglycans and Tamm-Horsfall protein are some substances that inhibit crystal aggregation. These substances play an important role in protecting normal subjects from stone formers. Abnormalities of these molecules might lead to stone formation i.e. a complex combination of inhibitors and promoters influence stone formation. Deficiency of inhibitors and an abundance of promoters in the urine facilitate stone formation, in addition to recognized dietary factors. The role of cell injury may be an even
more important determinant in the promotion and progression of kidney stones. Perhaps the presence of the stone itself initiates crystal growth leading to further epithelial disruption and progression of stone formation. All these considerations need further research in fields of assessment of role of inhibitors and promoters in renal stone formation.

REFERENCES


